9th Annual Medical Communications and Dissemination of Scientific Information Conference

September 14-16, 2020 | Virtual Event

DAY TWO | TUESDAY, APRIL 7

8:30 REGISTRATION & WELCOME COFFEE

8:55 CHAIRPERSON’S OPENING REMARKS

9:00 MULTI-STATION WORKSHOP: TAILORING CONTENT DEVELOPMENT STRATEGIES FOR SPECIFIC OUTREACH PLANS
The foundation of medical communication messaging is the premise that all information is centered on scientifically proven product data and is not centered on the market promotion of the product. While the goal of the messages is a very specific one, there are a multitude of dissemination avenues available to life science organizations and the intended outreach strategy does have a large impact on how information is packaged. This multi-station workshop allows attendees to address content considerations for a variety of available traditional and digital communication opportunities.

STATION ONE: Slide decks
Preeti Joshi, EPIZYME

STATION TWO: Congress materials
Kimberly Della Penna, MERCK

 

10:00 KNOWLEDGE LEADER ENGAGEMENT STRATEGIES FOR RARE DISEASE PRODUCTS
The key defining factor of a rare disease product is that the population of patients is relatively niche and concurrently that leads to a small group of individuals, including healthcare providers and industry experts, which are knowledgeable of the disease state. As medical communication teams often liaise and rely on the expertise of industry leaders to collaborate on publications and other messaging content, it is critical for medical communication executives to recruit and establish relationships with HCPs, consultants and KOLs early in a products life cycle. By exploring engagement strategies for key HCPS, executives will be better equipped to ensure necessary industry experts are available for medical communication operational needs.

Olivier Morteau, Associate Director, Scientific Communications, ALEXION PHARMACEUTICALS

 

10:45 COFFEE AND NETWORKING BREAK

 

11:15 DISEASE AWARENESS COMMUNICATION WITHIN RARE DISEASE THERAPEUTIC AREAS

  • Changes in content & messaging with awareness data packages
  • Opportunities in disease awareness for interactive outreach
    • Videos
    • Shareable images
    • Animations
  • Strategies for measuring engagement in awareness campaigns

Scott Baver, Director, Medical Communications, RHYTHM PHARMACEUTICALS

 

12:00 PANEL DISCUSSION: FIELD MEDICAL INSIGHT INTO THE UTILIZATION OF PRODUCT MATERIALS

  • Effective materials used by field-based teams
  • Frequent questions & feedback from HCPs
  • Gap analysis of materials used in the field
  • Collaboration with med comm teams

Elizabeth Lathers, EMD SERONO

Alan Polnariev, FERRING PHARMACEUTICALS

Jay Mashburn, ALLERGAN

Anita Goyal, MERCK

 

12:45 LUNCHEON FOR ALL SPEAKERS, SPONSORS & ATTENDEES

 

1:45 SMALL GROUP DISCUSSIONS: ADVOCACY PERSPECTIVE REGARDING PRODUCT INFORMATION MESSAGING
Medical communication teams are tasked with ensuring compliant, transparent, and medically based content reaches a variety of industry stakeholders ranging from HCPs, patients and caregivers. Each therapeutic area offers a variety of challenges due to the complexity of the disease state, type of care required and the longevity of treatment plans. Through small group discussions that are categorized by therapeutic areas and facilitated by patient advocates, executives will gain insight into the content and outreach needs of different patient groups to ensure medical product data is truly reaching intended audiences.

GROUP ONE: Kristina Davidson, HORIZON PHARMACEUTICALS

GROUP TWO: Kevin Bernier, BAYER HEALTHCARE

GROUP THREE: Lauren Chiarello, BIOGEN

 

2:30 STREAMLINING PUBLICATION OPERATIONS THROUGH COMPREHENSIVE PROJECT MANAGEMENT
A critical component of publication strategies is not only the data to be presented but the authors who are tasked with the composition of the articles and white papers. The key challenge for publication teams who are responsible for journal publication oversight is the supervision of authors, project management tasks and deadlines are the responsibility of those within the manufacturer’s publication teams. This case study will highlight essential components associated with overall project management to ensure streamline and timely publication processes.

  • Timeline development for manuscript creation
  • Engagement of necessary authors for articles
  • Communication of deadline expectations
  • Completion of authorship agreements

Ana Bozas, Associate Director, Global Medical Communications, AKCEA THERAPEUTICS

 

3:15 COFFEE AND NETWORKING BREAK

 

3:30 INCLUSION OF REAL WORLD EVIDENCE INTO JOURNAL PUBLICATIONS
The increased call for transparency from regulators, healthcare personnel and consumers has directly correlated to the rise in conversation about the availability of real world evidence for public review. While postmarket studies garner a plethora of data, organizations are exploring what the viable and responsible avenue of distribution is to release RWE product information. As one of the primary resources for therapeutic information is journal articles, executives must take into consideration the when and where before publishing this data.

  • Integrating RWE focused articles in publication strategies
  • Timeline for authorship and release of product RWE
  • Consideration for publication avenues: online vs. print

Iwona Bucior, Director, Medical Communications, MYOKARDIA

 

4:15 PROMOTING USE OF PRODUCT MEDICAL PUBLICATIONS FOR DOWNSTREAM OPERATIONS
Throughout a product’s lifecycle medical communication and publication executives will cultivate and develop a plethora of different content messages including journal articles, congress materials and scientifically based slide decks. While most materials have very targeted uses, organizations are exploring how to best deploy, these content rich materials in a variety of innovative avenues to best utilize information derived from medical communication teams. It is essential for companies to explore how to best continue the outreach and impact of messaging developed early in a product’s lifecycle to enhance and extend the impact of a therapy’s clinical and outcomes data.

Leah Eardley, Director of Global Medical Communications, VERTEX PHARMACEUTICALS

 

5:00 END OF CONFERENCE